ReviewMolecules (Basel, Switzerland)2015
Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 48 citations in OpenAlex.
- Review of Methods for DetectionJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Anti-Heliyon · 2024Article
- Vonoprazan a novel potassium competitive acid blocker; another leap forward.Przeglad gastroenterologiczny · 2024Article
- Exploration of Tuina Effect and Mechanism in Chronic Atrophic Gastritis Rats.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Overview ofGut and liver · 2021Review
- Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in EradicatingMiddle East journal of digestive diseases · 2021Article
- Evaluation of Better Staining Method among Hematoxylin and Eosin, Giemsa and Periodic Acid Schiff-Alcian Blue for the Detection of Helicobacter pylori in Gastric Biopsies.The Malaysian journal of medical sciences : MJMS · 2020Article
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- Observational
- Alternative eradication regimens forInfection and drug resistance · 2019Article
- Initial Trials With Susceptibility-Based and Empiric Anti-Frontiers in pharmacology · 2019Article
- Anti-Helicobacter pylori Activity of Isocoumarin Paepalantine: Morphological and Molecular Docking Analysis.Molecules (Basel, Switzerland) · 2017Article
- Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment forThe American journal of tropical medicine and hygiene · 2017Article
- Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.BMC microbiology · 2016Article
- Article
- Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
Asia has the largest population of any continent and the highest incidence of gastric cancer in the world, making it very important in the context of Helicobacter pylori infection. According to current guidelines, standard triple therapy containing a proton pump inhibitor (PPI) and two antibiotics; amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is still the preferred first-line regimen for treatment of H. pylori infection. However, the efficacy of legacy triple regimens has been seriously challenged, and they are gradually becoming ineffective. Moreover, some regions in Asia show patterns of emerging antimicrobial resistance. More effective regimens including the bismuth and non-bismuth quadruple, sequential, and dual-concomitant (hybrid) regimens are now replacing standard triple therapies as empirical first-line treatments on the basis of the understanding of the local prevalence of H. pylori antimicrobial resistance. Selection of PPI metabolized by the non-enzymatic pathway or minimal first pass metabolism and/or increasing dose of PPI are important to increase H. pylori eradication rates. Therefore, local antibiotic resistance surveillance updates, selection of appropriate first-line regimens with non-enzymatic PPI and/or increased doses of PPI, and detailed evaluation of patients' prior antibiotic usage are all essential information to combat H. pylori antibiotic resistance in Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.